Ancora Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Formed by some of the leading experts in carbohydrate chemistry and biology, Ancora Pharmaceuticals Inc. is among the young companies attempting to break the carbohydrate drug discovery bottleneck. The company will use its automated method for synthesizing complex carbohydrates as a springboard for drug development across a number of therapeutic areas.
You may also be interested in...
Glycan Biosciences Inc.
While recent advances have revealed the chemical structures of glycosaminoglycans and their enormous biological importance, cost-effective and scalable synthesis has been a consistent barrier to commercialization. Glycan Biosciences thinks it's solved the problem with its chemistry platform, Glycolink, which uses inexpensive pharmaceutical-grade feedstocks, simplified chemistry, and employs only a few steps. The technology has yielded numerous promising NCEs, including some for respiratory disease, Glycan's primary therapeutic target.
Glycobiology's Second Wave
New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.
Glycobiology's Second Wave
New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.